Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial.

Nobilis Therapeutics, Inc. announced today the completion and formal registration of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. Please read the full announcement by following the link.